{"url_path":"/sec/apvo/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-221593-index.html","accession_number":"0001193125-26-221593","cik":"0001671584","ticker":"APVO","issuer_name":"Aptevo Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-221593-index.html","primary_entity_key":"0001671584","primary_entity_name":"Aptevo Therapeutics Inc."},"word_count":81,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No.\n\nDescription\n\n99.1\n\n[Press Release dated May 13, 2026.](apvo-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAPTEVO THERAPEUTICS INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 13, 2026\n\nBy:\n\n/s/ Daphne Taylor\n\n \n\n \n\n \n\nDaphne Taylor\nSenior Vice President and Chief Financial Officer"}